Sign In
Buy NEO
$11.47
+0.270 (+2.41%)
At Close: Jun 23, 2026
NeOnc Technologies Receives UAE IND Approval for NEO100, Expanding Global Development Ahead of Anticipated Phase 2 Data Milestone
09:00am, Tuesday, 23'rd Jun 2026
Authorization covers all three NEO100 programs across adult Phase 1 through Phase 2, plus pediatric studies Extends NeOnc's UAE footprint beyond NEO212 and complements ongoing U.S. development, where
NeoGenomics (NEO) Soars 7.2%: Is Further Upside Left in the Stock?
08:10am, Friday, 19'th Jun 2026
NeoGenomics (NEO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Neo Performance Materials Inc. (NEO:CA) Shareholder/Analyst Call Prepared Remarks Transcript
05:42pm, Wednesday, 17'th Jun 2026
Neo Performance Materials Inc. (NEO:CA) Shareholder/Analyst Call Prepared Remarks Transcript
NeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior Notes
06:00am, Wednesday, 17'th Jun 2026
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior Notes.
Employers Tighten Focus on AI and Human Skills as Global Tech Hiring Moderates
12:00pm, Tuesday, 16'th Jun 2026
Employers Tighten Focus on AI and Human Skills as Global Tech Hiring Moderates PR Newswire MILWAUKEE, June 16, 2
Clearance enables Phase 2 evaluation of NEO212, the Company's oral perillyl alcohol-temozolomide conjugate, in the United Arab Emirates Follows completion of Phase 1 dose escalation and selection of 6
NeoGenomics Announces Proposed Offering of $275 Million Convertible Senior Notes
05:24pm, Monday, 15'th Jun 2026
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics Announces Proposed Offering of $275 Million Convertible Senior Notes.
NeoGenomics Inc (NEO) Stock Up 6.5% and Still Undervalued -- GF Score: 68/100
08:54pm, Thursday, 28'th May 2026
On May 28, 2026, NeoGenomics Inc (NEO) shares rose 6.5% today, closing at $10.19. This movement comes amid a 52-week trading range between $4.72 and $13.74, ref
Neo Performance Materials Announces C$100 Million Bought Deal Treasury Offering of Common Shares
04:20pm, Wednesday, 20'th May 2026
The base shelf prospectus is accessible, and the prospectus supplement will be accessible within two business days through SEDAR+ The base shelf prospectus is accessible, and the prospectus supplement
Neo Partners with Greenland Mines to Advance Sarfartoq Rare Earth Project
04:15pm, Wednesday, 20'th May 2026
Strategic partnership positions Greenland Mines to lead exploration while Neo retains equity stake and offtake rights Strategic partnership positions Greenland Mines to lead exploration while Neo reta
NeoGenomics to Participate in Upcoming Investor Conferences
10:00am, Friday, 15'th May 2026
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the Company will participat
NeoGenomics to Participate in Upcoming Investor Conferences
09:05am, Friday, 15'th May 2026
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the Company will participate in t
Neo Performance Materials Inc. (NEO:CA) Q1 2026 Earnings Call Transcript
01:00pm, Tuesday, 12'th May 2026
Neo Performance Materials Inc. (NEO:CA) Q1 2026 Earnings Call Transcript
Medicenna and Fondazione Melanoma Onlus Announce First Patient Dosed in the NEO-CYT Study of MDNA11 in Neoadjuvant Melanoma
07:00am, Tuesday, 12'th May 2026
NEO-CYT marks the first evaluation of MDNA11 in earlier-stage cancers, as a potentially curative treatment; extends development beyond the heavily pretreated metastatic setting of the ongoing Phase 1/
NeOnc CEO Accelerates Insider Buying with $500K+ Investment Ahead of Imminent NEO100 Phase 2a Data Catalysts
09:00am, Tuesday, 05'th May 2026
CALABASAS, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company focused on advancing
